Jacques (Sjaak) Neefjes(born 8 December 1959) is a Dutch scientist who made breakthroughs in several research disciplines such asimmunology,cell biology,chemistry,cancer biology,microbiology,andepidemiology.He is a professor at theLeiden University Medical Center.In 2020 he was one of four winners of theSpinoza Prize.
Jacques Neefjes | |
---|---|
Sjaak Neefjes | |
![]() | |
Born | 8 December 1959 | (age64)
Nationality | Dutch |
Education | |
Scientific career | |
Institutions | Leiden University Medical Center |
Biography
editFrom 1979 to 1985, Jacques Neefjes studied Chemistry at theVrije Universiteit Amsterdam.Then, he performed his Ph.D. studies at the Division of Cellular Biochemistry, in theNetherlands Cancer Institute(NKI) under the supervision of Prof. Dr. Ploegh in Amsterdam. During his thesis, he investigated theCell Biological Aspect of MHC class I and II molecules.He obtained his Ph.D. degree on the 2nd of November 1990 withCum Laude.
After his Ph.D., Jacques Neefjes did two post-doctoral visits. First, from 1991 to 1992, he visited the laboratory of Drs Benoit and Mathis at the Institut de Chimie Biologique, Strasbourg (France). Then, he obtained a 2-year fellowship from theEuropean Molecular Biology Organization(EMBO) to visit the laboratory of Prof. Dr. Hämmerling at theGerman Cancer Research Center(DKFZ), in Heidelberg (Germany) from 1992 to 1993. In 1993, Jacques Neefjes became a staff member of the Division of Cellular Biochemistry at theNKI.In 1998, he became head of the division of Tumor Biology. From 1999 to 2016, he occupied the position of "Extraordinary professor" at theLeiden University.He was the Dean of the Graduate School Oncology Amsterdam (OOA) from 2000 to 2003.
Since 2016, he is head of the Cell and Chemical Biology department at theLeiden University Medical Center(the Netherlands).
Works
editDuring his career, Jacques Neefjes has authored more than 280scientific publicationsreaching more than 30,000 citations.[1]Neefjes’ discoveries onantigen presentationby the class I and IImajor histocompatibility complexes(MHC) constitute today's textbook knowledge. Through his exploration of the cell biology of the MHC, Jacques Neefjes became an expert onendocytosisandintracellular transport.In 2017, Neefjes and his team made fundamental discoveries regarding endosome positioning by the endoplasmic reticulum.[2]Neefjes further expanded his work onendosomestophagosomesandintracellularbacteria.By combiningchemistry,cell biologyandbiochemistrywithgenetic screens,Neefjes identifiedinhibitorsto disturb bacterial survival strategies, representing one of the firstantibioticsacting by targeting the host, rather than thepathogen.[3]In 2015, Neefjes has demonstrated thatSalmonellainfection promotecancerdevelopment.[4]Since 2019, Jacques Neefjes is co-financing the production of a promisingcancer drug,Aclarubicin,which disappeared from the European market at the beginning of the 21st century.[5][6][7]
Distinction
editHonours and awards
edit- 1990Antonie van Leeuwenhoekaward
- 1996 Golden Medal of theRoyal Dutch Chemical Society(KNCV)
- 2007 Elected as a member ofEuropean Molecular Biology Organization(EMBO)
- 2010 Elected as a member at the European Academy of Cancer Sciences
- 2013 Elected as a member ofAcademia Europaea[8]
- 2013 Recipient and main applicant for the Gravity Program at the Institute for Chemical Immunology ICI
- 2014 Elected as a member of theNorwegian Academy of Science and Letters(Det Norske Videnskaps-Akademi)[9]
- 2015 Elected as a member and Dutch representative in theEuropean Cooperation in Science and TechnologyCommittee
- 2015 Elected as a member of theRoyal Netherlands Academy of Arts and Sciences(KNAW)[10]
- 2015 van Loghem Lecture, the annual career award for research in Immunology from the Dutch Immunology Society NVVI
- 2019 Josephine Nefkens Award for cancer research
- 2020Spinoza Prize[11]
Honorary Lectures
edit- 2012 Ruysch lecture AMC, Amsterdam
- 2012 Beatty Lecture, McGill University, Montreal, Canada
Selected research articles
editThe Biosynthetic Pathway of MHC Class II but Not Class I Molecules Intersects the Endocytic Route.
Neefjes JJ, Stollorx V, Peters PJ, Geuze HJ, and Ploegh HL.
Cell. 1990. 61:171-183.
The major substrates for TAP in vivo are derived from newly synthesized proteins.
Reits EA, Vos JC, Grommé M, and Neefjes JJ.
Nature. 2000. 404:774–778.
Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1.
Kuijl C, Savage ND, Marsman M, Tuin AW, Janssen L, Egan DA, Ketema M, Van Den Nieuwendijk R, Van Den Eeden SJ, Geluk A, Poot A, Van Der Marel G, Beijersbergen RL, Overkleeft H, Ottenhoff TH, and Neefjes JJ.
Nature. 2007. 450:725–730
An ER-Associated Pathway Defines Endosomal Architecture for Controlled Cargo Transport.
Jongsma ML, Berlin I, Wijdeven RH, Janssen L, Janssen GM, Garstka MA, Janssen H, Mensink M, van Veelen PA, Spaapen RM, and Neefjes JJ.
Cell. 2016. 166:152-166
References
edit- ^"Jacques Neefjes".
- ^Jongsma, Marlieke L.M.; Berlin, Ilana; Wijdeven, Ruud H.M.; Janssen, Lennert; Janssen, George M.C.; Garstka, Malgorzata A.; Janssen, Hans; Mensink, Mark; van Veelen, Peter A.; Spaapen, Robbert M.; Neefjes, Jacques (June 2016)."An ER-Associated Pathway Defines Endosomal Architecture for Controlled Cargo Transport".Cell.166(1): 152–166.doi:10.1016/j.cell.2016.05.078.PMC4930482.PMID27368102.
- ^Kuijl, Coenraad; Savage, Nigel D. L.; Marsman, Marije; Tuin, Adriaan W.; Janssen, Lennert; Egan, David A.; Ketema, Mirjam; van den Nieuwendijk, Rian; van den Eeden, Susan J. F.; Geluk, Annemieke; Poot, Alex (November 2007). "Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1".Nature.450(7170): 725–730.Bibcode:2007Natur.450..725K.doi:10.1038/nature06345.hdl:1887/3209535.ISSN0028-0836.PMID18046412.S2CID23274247.
- ^Scanu, Tiziana; Spaapen, Robbert M.; Bakker, Jeroen M.; Pratap, Chandra Bhan; Wu, Lin-en; Hofland, Ingrid; Broeks, Annegien; Shukla, Vijay Kumar; Kumar, Mohan; Janssen, Hans; Song, Ji-Ying (2015-06-10)."Salmonella Manipulation of Host Signaling Pathways Provokes Cellular Transformation Associated with Gallbladder Carcinoma".Cell Host & Microbe.17(6): 763–774.doi:10.1016/j.chom.2015.05.002.ISSN1931-3128.PMID26028364.
- ^de Visser, Ellen; van der Zwaal, Manon; Jockel, Judith (March 2, 2019)."Hoe de erfenis van Els Borst mogelijk kankerpatiënten kan helpen".Volkskrant Kijk Verder(in Dutch).Retrieved2019-10-02.
- ^"Nooit de makkelijkste weg - interview met Sjaak Neefjes, hoogleraar chemische immunologie aan de Universiteit Leiden en spreker op 2 oktober".Labtechnology(in Dutch). 2019-09-16.Retrieved2019-10-02.
- ^Visser, Ellen de (2019-03-02)."Oud-minister Els Borst helpt postuum mee aan terugkeer kankermedicijn".de Volkskrant(in Dutch).Retrieved2019-10-02.
- ^"Jacques Neefjes".Academia Europaea. Archived fromthe originalon 28 March 2019.
- ^"Group 6: Cellular and Molecular biology".Norwegian Academy of Science and Letters.Retrieved11 April2020.
- ^"Jacques Neefjes".Royal Netherlands Academy of Arts and Sciences. Archived fromthe originalon 24 September 2019.
- ^"Prof. Sjaak Neefjes".Netherlands Organisation for Scientific Research. Archived fromthe originalon 6 November 2020.